Pharmacokinetic and Pharmacogenetic Predictive Markers of Irinotecan Activity and Toxicity

Current Drug Metabolism

Volumn 12, Issue 10, 2011, Pages 932-943

  Di Paolo, Antonello ^a   Bocci, Guido ^a   Polillo, Marialuisa ^a   Del Re, Marzia ^a   Di Desidero, Teresa ^a   Lastella, Marianna ^a   Danesi, Romano ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Effectiveness; Irinotecan; Pharmacogenetics; Pharmacokinetics; Toxicity

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; BIOLOGICAL MARKER; BREAST CANCER RESISTANCE PROTEIN; CYTOCHROME P450 4A; GLUCURONOSYLTRANSFERASE 1A1; IRINOTECAN; MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC ANION TRANSPORTER 2; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; TUMOR MARKER;

ARTICLE; CANCER PATIENT; DIARRHEA; DNA POLYMORPHISM; DRUG ACTIVITY; DRUG METABOLISM; GENOTYPE; HUMAN; MAXIMUM PLASMA CONCENTRATION; NEUTROPENIA; SENSITIVITY AND SPECIFICITY; COLORECTAL TUMOR; GENETIC POLYMORPHISM; GENETICS; METABOLISM; PERSONALIZED MEDICINE; REVIEW;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; COLORECTAL NEOPLASMS; HUMANS; INDIVIDUALIZED MEDICINE; POLYMORPHISM, GENETIC; TUMOR MARKERS, BIOLOGICAL;

EID: 82255195550     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920011798062283     Document Type: Article

References (103)

1. Braun, A. H.; Achterrath, W.; Wilke, H.; Vanhoefer, U.; Harstrick, A.; Preusser, P. New systemic frontline treatment for metastatic co-lorectal carcinoma. Cancer, 2004, 100(8), 1558-1577. (Pubitemid 38460946)
2. Douillard, J. Y.; Sobrero, A.; Carnaghi, C.; Comella, P.; Diaz-Rubio, E.; Santoro, A.; Van Cutsem, E. Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy. Ann. Oncol., 2003, 14 Suppl 2, ii 7-12. (Pubitemid 36874132)
3. Di Paolo, A.; Bocci, G.; Danesi, R.; Del Tacca, M. Clinical pharmacokinetics of irinotecan-based chemotherapy in colorectal cancer patients. Curr. Clin. Pharmacol., 2006, 1(3), 311-323.
4. Chabot, G. G. Clinical pharmacokinetics of irinotecan. Clin. Phar-macokinet., 1997, 33(4), 245-259. (Pubitemid 27429892)
5. Danks, M. K.; Morton, C. L.; Pawlik, C. A.; Potter, P. M. Overexpression of a rabbit liver carboxylesterase sensitizes human tumor cells to CPT-11. Cancer Res., 1998, 58(1), 20-22. (Pubitemid 28027709)
6. Yano, H.; Kayukawa, S.; Iida, S.; Nakagawa, C.; Oguri, T.; Sanda, T.; Ding, J.; Mori, F.; Ito, A.; Ri, M.; Inagaki, A.; Kusumoto, S.; Ishida, T.; Komatsu, H.; Inagaki, H.; Suzuki, A.; Ueda, R. Overex-pression of carboxylesterase-2 results in enhanced efficacy of topoisomerase I inhibitor, irinotecan (CPT-11), for multiple myeloma. Cancer Sci., 2008, 99(11), 2309-2314.
7. Hatfield, M. J.; Tsurkan, L.; Garrett, M.; Shaver, T. M.; Hyatt, J. L.; Edwards, C. C.; Hicks, L. D.; Potter, P. M. Organ-specific carboxy-lesterase profiling identifies the small intestine and kidney as major contributors of activation of the anticancer prodrug CPT-11. Bio-chem. Pharmacol., 2011, 81(1), 24-31.
8. Guemei, A. A.; Cottrell, J.; Band, R.; Hehman, H.; Prudhomme, M.; Pavlov, M. V.; Grem, J. L.; Ismail, A. S.; Bowen, D.; Taylor, R. E.; Takimoto, C. H. Human plasma carboxylesterase and butyrylcho-linesterase enzyme activity: correlations with SN-38 pharmacoki-netics during a prolonged infusion of irinotecan. Cancer Che-mother. Pharmacol., 2001, 47(4), 283-290. (Pubitemid 32640767)
9. Cecchin, E.; Corona, G.; Masier, S.; Biason, P.; Cattarossi, G.; Frustaci, S.; Buonadonna, A.; Colussi, A.; Toffoli, G. Carboxyles-terase isoform 2 mRNA expression in peripheral blood mononu-clear cells is a predictive marker of the irinotecan to SN38 activation step in colorectal cancer patients. Clin. Cancer Res., 2005, 11(19 Pt 1), 6901-6907. (Pubitemid 41428747)
10. Santos, A.; Zanetta, S.; Cresteil, T.; Deroussent, A.; Pein, F.; Raymond, E.; Vernillet, L.; Risse, M. L.; Boige, V.; Gouyette, A.; Vassal, G. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin. Cancer Res., 2000, 6(5), 2012-2020. (Pubitemid 30305100)
11. Ando, Y.; Saka, H.; Asai, G.; Sugiura, S.; Shimokata, K.; Kama-taki, T. UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan. Ann. Oncol., 1998, 9(8), 845-847. (Pubitemid 28440442)
12. Lankisch, T. O.; Schulz, C.; Zwingers, T.; Erichsen, T. J.; Manns, M. P.; Heinemann, V.; Strassburg, C. P. Gilbert's Syndrome and iri-notecan toxicity: combination with UDP-glucuronosyltransferase 1A7 variants increases risk. Cancer Epidemiol. Biomarkers Prev., 2008, 17(3), 695-701. (Pubitemid 351469222)
13. Cecchin, E.; Innocenti, F.; D'Andrea, M.; Corona, G.; De Mattia, E.; Biason, P.; Buonadonna, A.; Toffoli, G. Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplo-types on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan. J. Clin. Oncol., 2009, 27(15), 2457-2465.
14. Slatter, J. G.; Schaaf, L. J.; Sams, J. P.; Feenstra, K. L.; Johnson, M. G.; Bombardt, P. A.; Cathcart, K. S.; Verburg, M. T.; Pearson, L. K.; Compton, L. D.; Miller, L. L.; Baker, D. S.; Pesheck, C. V.; Lord, R. S., 3rd. Pharmacokinetics, metabolism, and excretion of ir-inotecan (CPT-11) following I. V. infusion of «(14)C» CPT-11 in cancer patients. Drug Metab. Dispos., 2000, 28(4), 423-433. (Pubitemid 30185681)
15. Sugiyama, Y.; Kato, Y.; Chu, X. Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular mul-tispecific organic anion transporter and P-glycoprotein. Cancer Chemother. Pharmacol., 1998. 42 Suppl, S44-49.
16. de Jong, F. A.; de Jonge, M. J.; Verweij, J.; Mathijssen, R. H. Role of pharmacogenetics in irinotecan therapy. Cancer Lett., 2006, 234(1), 90-106. (Pubitemid 43343943)
17. de Jong, F. A.; Marsh, S.; Mathijssen, R. H.; King, C.; Verweij, J.; Sparreboom, A.; McLeod, H. L. ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on iri-notecan disposition. Clin. Cancer Res., 2004, 10(17), 5889-5894. (Pubitemid 39180970)
18. Kehrer, D. F.; Yamamoto, W.; Verweij, J.; de Jonge, M. J.; de Bruijn, P.; Sparreboom, A. Factors involved in prolongation of the terminal disposition phase of SN-38: clinical and experimental studies. Clin Cancer Res., 2000, 6(9), 3451-3458.
19. Pommier, Y.; Pourquier, P.; Fan, Y.; Strumberg, D. Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. Biochim. Biophys. Acta, 1998, 1400(1-3), 83-105.
20. Masi, G.; Falcone, A.; Di Paolo, A.; Allegrini, G.; Danesi, R.; Barbara, C.; Cupini, S.; Del Tacca, M. A phase I and pharmacokinetic study of irinotecan given as a 7-day continuous infusion in metas-tatic colorectal cancer patients pretreated with 5-fluorouracil or ral-titrexed. Clin. Cancer Res., 2004, 10(5), 1657-1663. (Pubitemid 38435555)
21. Allegrini, G.; Falcone, A.; Fioravanti, A.; Barletta, M. T.; Orlandi, P.; Loupakis, F.; Cerri, E.; Masi, G.; Di Paolo, A.; Kerbel, R. S.; Danesi, R.; Del Tacca, M.; Bocci, G. A pharmacokinetic and phar-macodynamic study on metronomic irinotecan in metastatic colo-rectal cancer patients. Br. J. Cancer, 2008, 98(8), 1312-1319. (Pubitemid 351543577)
22. Raymond, E.; Boige, V.; Faivre, S.; Sanderink, G. J.; Rixe, O.; Vernillet, L.; Jacques, C.; Gatineau, M.; Ducreux, M.; Armand, J. P. Dosage adjustment and pharmacokinetic profile of irinotecan in cancer patients with hepatic dysfunction. J. Clin. Oncol., 2002, 20(21), 4303-4312. (Pubitemid 35266290)
23. Strassburg, C. P. Pharmacogenetics of Gilbert's syndrome. Pharma-cogenomics, 2008, 9(6), 703-715.
24. Sai, K.; Saeki, M.; Saito, Y.; Ozawa, S.; Katori, N.; Jinno, H.; Ha-segawa, R.; Kaniwa, N.; Sawada, J.; Komamura, K.; Ueno, K.; Kamakura, S.; Kitakaze, M.; Kitamura, Y.; Kamatani, N.; Minami, H.; Ohtsu, A.; Shirao, K.; Yoshida, T.; Saijo, N. UGT1A1 haplo-types associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer. Clin. Pharmacol. Ther., 2004, 75(6), 501-515. (Pubitemid 38746601)
25. Meyerhardt, J. A.; Kwok, A.; Ratain, M. J.; McGovren, J. P.; Fuchs, C. S. Relationship of baseline serum bilirubin to efficacy and toxic-ity of single-agent irinotecan in patients with metastatic colorectal cancer. J. Clin. Oncol., 2004, 22(8), 1439-1446. (Pubitemid 41103626)
26. Innocenti, F.; Undevia, S. D.; Iyer, L.; Chen, P. X.; Das, S.; Kocher-ginsky, M.; Karrison, T.; Janisch, L.; Ramirez, J.; Rudin, C. M.; Vokes, E. E.; Ratain, M. J. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutro-penia of irinotecan. J. Clin. Oncol., 2004, 22(8), 1382-1388. (Pubitemid 41103619)
27. Rouits, E.; Charasson, V.; Petain, A.; Boisdron-Celle, M.; Delord, J. P.; Fonck, M.; Laurand, A.; Poirier, A. L.; Morel, A.; Chatelut, E.; Robert, J.; Gamelin, E. Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients. Br. J. Cancer, 2008, 99(8), 1239-1245.
28. Gupta, E.; Lestingi, T. M.; Mick, R.; Ramirez, J.; Vokes, E. E.; Ratain, M. J. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res., 1994, 54(14), 3723-3725. (Pubitemid 24241187)
29. Xie, R.; Mathijssen, R. H.; Sparreboom, A.; Verweij, J.; Karlsson, M. O. Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea. Clin. Pharmacol. Ther., 2002, 72(3), 265-275.
30. Toffoli, G.; Cecchin, E.; Corona, G.; Russo, A.; Buonadonna, A.; D'Andrea, M.; Pasetto, L. M.; Pessa, S.; Errante, D.; De Pangher, V.; Giusto, M.; Medici, M.; Gaion, F.; Sandri, P.; Galligioni, E.; Bonura, S.; Boccalon, M.; Biason, P.; Frustaci, S. The role of UGT1A1*28 polymorphism in the pharmacodynamics and phar-macokinetics of irinotecan in patients with metastatic colorectal cancer. J. Clin. Oncol., 2006, 24(19), 3061-3068. (Pubitemid 46638941)
31. Canal, P.; Gay, C.; Dezeuze, A.; Douillard, J. Y.; Bugat, R.; Brunet, R.; Adenis, A.; Herait, P.; Lokiec, F.; Mathieu-Boue, A. Pharma-cokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer. J. Clin. Oncol., 1996, 14(10), 2688-2695.
32. van der Bol, J. M.; Mathijssen, R. H.; Loos, W. J.; Friberg, L. E.; van Schaik, R. H.; de Jonge, M. J.; Planting, A. S.; Verweij, J.; Sparre-boom, A.; de Jong, F. A. Cigarette smoking and irinotecan treatment: pharmacokinetic interaction and effects on neutropenia. J. Clin. Oncol., 2007, 25(19), 2719-2726. (Pubitemid 47123179)
33. Morimoto, S.; Matsuura, I.; Shono, Y.; Horiuchi, T.; Nakajima, Y.; Miyabe, T.; Hachino, Y.; Hasegawa, K.; Matsuyama, K.; Fujita, Y.; Tabuse, K. Individual differences in rate-limiting reactions during metabolism of irinotecan hydrochloride. Gan To Kagaku Ryoho, 2009, 36(7), 1135-1140.
34. Hennebelle, I.; Terret, C.; Chatelut, E.; Bugat, R.; Canal, P.; Guichard, S. Characterization of CPT-11 converting carboxyles-terase activity in colon tumor and normal tissues: comparison with p-nitro-phenylacetate converting carboxylesterase activity. Anti-cancer Drugs, 2000, 11(6), 465-470.
35. Falcone, A.; Di Paolo, A.; Masi, G.; Allegrini, G.; Danesi, R.; Len-cioni, M.; Pfanner, E.; Comis, S.; Del Tacca, M.; Conte, P. Sequence effect of irinotecan and fluorouracil treatment on pharma-cokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients. J. Clin. Oncol., 2001, 19(15), 3456-3462. (Pubitemid 32730081)
36. Mick, R.; Gupta, E.; Vokes, E. E.; Ratain, M. J. Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity. J. Clin. Oncol., 1996, 14(7), 2012-2019. (Pubitemid 26230101)
37. van der Bol, J. M.; Mathijssen, R. H.; Creemers, G. J.; Planting, A. S.; Loos, W. J.; Wiemer, E. A.; Friberg, L. E.; Verweij, J.; Sparreboom, A.; de Jong, F. A. A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan. Clin. Cancer Res., 2010, 16(2), 736-742.
38. Bansal, T.; Awasthi, A.; Jaggi, M.; Khar, R. K.; Talegaonkar, S. Development and validation of reversed phase liquid chroma-tographic method utilizing ultraviolet detection for quantification of irinotecan (CPT-11) and its active metabolite, SN-38, in rat plasma and bile samples: application to pharmacokinetic studies. Talanta, 2008, 76(5), 1015-1021.
39. Blandizzi, C.; Danesi, R.; De Paolis, B.; Di Paolo, A.; Colucci, R.; Falcone, A.; Del Tacca, M. Cholinergic toxic syndrome by the anticancer drug irinotecan: acetylcholinesterase does not play a major role. Clin. Pharmacol. Ther., 2002, 71(4), 263-271. (Pubitemid 34311455)
40. Poujol, S.; Pinguet, F.; Malosse, F.; Astre, C.; Ychou, M.; Culine, S.; Bressolle, F. Sensitive HPLC-fluorescence method for irinote-can and four major metabolites in human plasma and saliva: application to pharmacokinetic studies. Clin. Chem., 2003, 49(11), 1900-1908. (Pubitemid 37340325)
41. Ramesh, M.; Ahlawat, P.; Srinivas, N. R. Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives. Biomed. Chroma-togr., 2010, 24(1), 104-123.
42. Poujol, S.; Pinguet, F.; Ychou, M.; Abderrahim, A. G.; Duffour, J.; Bressolle, F. M. A limited sampling strategy to estimate the phar-macokinetic parameters of irinotecan and its active metabolite, SN-38, in patients with metastatic digestive cancer receiving the FOLFIRI regimen. Oncol. Rep., 2007, 18(6), 1613-321.
43. Miya, T.; Goya, T.; Fujii, H.; Ohtsu, T.; Itoh, K.; Igarashi, T.; Mi-nami, H.; Sasaki, Y. Factors affecting the pharmacokinetics of CPT-11: the body mass index, age and sex are independent predictors of pharmacokinetic parameters of CPT-11. Invest. New Drugs, 2001, 19(1), 61-67. (Pubitemid 32209785)
44. Bomgaars, L. R.; Bernstein, M.; Krailo, M.; Kadota, R.; Das, S.; Chen, Z.; Adamson, P. C.; Blaney, S. M. Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study. J. Clin. Oncol., 2007, 25(29), 4622-4627. (Pubitemid 350035322)
45. Stewart, C. F.; Panetta, J. C.; O'Shaughnessy, M. A.; Throm, S. L.; Fraga, C. H.; Owens, T.; Liu, T.; Billups, C.; Rodriguez-Galindo, C.; Gajjar, A.; Furman, W. L.; McGregor, L. M. UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan. J. Clin. Oncol., 2007, 25(18), [2594-2600. (Pubitemid 47041233)
46. Iolascon, A.; Perrotta, S.; Coppola, B.; Carbone, R.; Miraglia Del Giudice, E. Frequency of Gilbert's syndrome associated with UGTA1 (TA) (7) polymorphism in Southern Italy. Haematologica, 2000, 85(3), 335-336. (Pubitemid 30340164)
47. Le Bihan-Levaufre, B.; Francoual, J.; Labrune, P.; Chalas, J.; Capel, L.; Lindenbaum, A. [Refinement and role of the diagnosis of Gilbert disease with molecular biology]. Ann. Biol. Clin. (Paris), 2001, 59(1), 61-66. (Pubitemid 32157701)
48. Iyer, L.; Das, S.; Janisch, L.; Wen, M.; Ramirez, J.; Karrison, T.; Fleming, G. F.; Vokes, E. E.; Schilsky, R. L.; Ratain, M. J. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J, 2002, 2(1), 43-47. (Pubitemid 34982202)
49. Martinez-Balibrea, E.; Abad, A.; Martinez-Cardus, A.; Gines, A.; Valladares, M.; Navarro, M.; Aranda, E.; Marcuello, E.; Benavides, M.; Massuti, B.; Carrato, A.; Layos, L.; Manzano, J. L.; Moreno, V. UGT1A and TYMS genetic variants predict toxicity and response of colorectal cancer patients treated with first-line irinotecan and fluorouracil combination therapy. Br. J. Cancer, 2010, 103(4), 581-589.
50. Ruzzo, A.; Graziano, F.; Loupakis, F.; Santini, D.; Catalano, V.; Bisonni, R.; Ficarelli, R.; Fontana, A.; Andreoni, F.; Falcone, A.; Canestrari, E.; Tonini, G.; Mari, D.; Lippe, P.; Pizzagalli, F.; Schiavon, G.; Alessandroni, P.; Giustini, L.; Maltese, P.; Testa, E.; Menichetti, E. T.; Magnani, M. Pharmacogenetic profiling in patients with advanced colorectal cancer treated with first-line FOLFIRI chemotherapy. Pharmacogenomics J., 2008, 8(4), 278-288. (Pubitemid 352038307)
51. Braun, M. S.; Richman, S. D.; Thompson, L.; Daly, C. L.; Meade, A. M.; Adlard, J. W.; Allan, J. M.; Parmar, M. K.; Quirke, P.; Seymour, M. T. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colo-rectal cancer: the FOCUS trial. J. Clin. Oncol., 2009, 27(33), 5519-5528.
52. McLeod, H. L.; Sargent, D. J.; Marsh, S.; Green, E. M.; King, C. R.; Fuchs, C. S.; Ramanathan, R. K.; Williamson, S. K.; Findlay, B. P.; Thibodeau, S. N.; Grothey, A.; Morton, R. F.; Goldberg, R. M. Pharmacogenetic predictors of adverse events and response to chemotherapy in metastatic colorectal cancer: results from North American Gastrointestinal Intergroup Trial N9741. J. Clin. Oncol., 2010, 28(20), 3227-3233.
53. Marcuello, E.; Altes, A.; Menoyo, A.; Del Rio, E.; Gomez-Pardo, M.; Baiget, M. UGT1A1 gene variations and irinotecan treatment in patients with metastatic colorectal cancer. Br. J. Cancer, 2004, 91(4), 678-682. (Pubitemid 39141623)
54. Schulz, C.; Heinemann, V.; Schalhorn, A.; Moosmann, N.; Zwing-ers, T.; Boeck, S.; Giessen, C.; Stemmler, H. J. UGT1A1 gene polymorphism: impact on toxicity and efficacy of irinotecan-based regimens in metastatic colorectal cancer. World J. Gastroenterol., 2009, 15(40), 5058-5066.
55. Boige, V.; Mendiboure, J.; Pignon, J. P.; Loriot, M. A.; Castaing, M.; Barrois, M.; Malka, D.; Tregouet, D. A.; Bouche, O.; Le Corre, D.; Miran, I.; Mulot, C.; Ducreux, M.; Beaune, P.; Laurent-Puig, P. Pharmacogenetic assessment of toxicity and outcome in patients with metastatic colorectal cancer treated with LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. J. Clin. Oncol., 2010, 28(15), 2556-2564.
56. Jada, S. R.; Lim, R.; Wong, C. I.; Shu, X.; Lee, S. C.; Zhou, Q.; Goh, B. C.; Chowbay, B. Role of UGT1A1*6, UGT1A1*28 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients. Cancer Sci., 2007, 98(9), 1461-1467. (Pubitemid 47241771)
57. Han, J. Y.; Lim, H. S.; Park, Y. H.; Lee, S. Y.; Lee, J. S. Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer. Lung. Cancer, 2009, 63(1), 115-120.
58. Biason, P.; Masier, S.; Toffoli, G. UGT1A1*28 and other UGT1A polymorphisms as determinants of irinotecan toxicity. J. Che-mother., 2008, 20(2), 158-165. (Pubitemid 351797053)
59. Minami, H.; Sai, K.; Saeki, M.; Saito, Y.; Ozawa, S.; Suzuki, K.; Kaniwa, N.; Sawada, J.; Hamaguchi, T.; Yamamoto, N.; Shirao, K.; Yamada, Y.; Ohmatsu, H.; Kubota, K.; Yoshida, T.; Ohtsu, A.; Saijo, N. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet. Genomics, 2007, 17(7), 497-504. (Pubitemid 46905216)
60. Yamamoto, N.; Takahashi, T.; Kunikane, H.; Masuda, N.; Eguchi, K.; Shibuya, M.; Takeda, Y.; Isobe, H.; Ogura, T.; Yokoyama, A.; Watanabe, K. Phase I/II pharmacokinetic and pharmacogenomic study of UGT1A1 polymorphism in elderly patients with advanced non-small cell lung cancer treated with irinotecan. Clin. Pharmacol. Ther., 2009, 85(2), 149-154.
61. Kitagawa, C.; Ando, M.; Ando, Y.; Sekido, Y.; Wakai, K.; Imai-zumi, K.; Shimokata, K.; Hasegawa, Y. Genetic polymorphism in the phenobarbital-responsive enhancer module of the UDP-glucuronosyltransferase 1A1 gene and irinotecan toxicity. Pharma-cogenet. Genomics, 2005, 15(1), 35-41. (Pubitemid 43205525)
62. Saito, Y.; Sai, K.; Maekawa, K.; Kaniwa, N.; Shirao, K.; Hamagu-chi, T.; Yamamoto, N.; Kunitoh, H.; Ohe, Y.; Yamada, Y.; Ta-mura, T.; Yoshida, T.; Minami, H.; Ohtsu, A.; Matsumura, Y.; Saijo, N.; Sawada, J. Close association of UGT1A9 IVS1÷399C>T with UGT1A1*28, *6, or *60 haplotype and its apparent influence on 7-ethyl-10-hydroxycamptothecin (SN-38) glucuronidation in Japanese. Drug Metab. Dispos., 2009, 37(2), 272-276.
63. Lara, P. N., Jr.; Natale, R.; Crowley, J.; Lenz, H. J.; Redman, M. W.; Carleton, J. E.; Jett, J.; Langer, C. J.; Kuebler, J. P.; Dakhil, S. R.; Chansky, K.; Gandara, D. R. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J. Clin. Oncol., 2009, 27(15), 2530-2535.
64. Park, S. R.; Kong, S. Y.; Rhee, J.; Park, Y. I.; Ryu, K. W.; Lee, J. H.; Kim, Y. W.; Choi, I. J.; Kim, C. G.; Lee, J. Y.; Cho, S. J.; Kim, N. K. Phase II study of a triplet regimen of S-1 combined with irinotecan and oxaliplatin in patients with metastatic gastric cancer: clinical and pharmacogenetic results. Ann. Oncol., 2011, 22(4), 890-896.
65. Charasson, V.; Bellott, R.; Meynard, D.; Longy, M.; Gorry, P.; Robert, J. Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38. Clin. Pharmacol. Ther., 2004, 76(6), 528-535. (Pubitemid 39601543)
66. Wu, M. H.; Chen, P.; Wu, X.; Liu, W.; Strom, S.; Das, S.; Cook, E. H., Jr.; Rosner, G. L.; Dolan, M. E. Determination and analysis of single nucleotide polymorphisms and haplotype structure of the human carboxylesterase 2 gene. Pharmacogenetics, 2004, 14(9), 595-605. (Pubitemid 39281814)
67. Kim, S. R.; Nakamura, T.; Saito, Y.; Sai, K.; Nakajima, T.; Saito, H.; Shirao, K.; Minami, H.; Ohtsu, A.; Yoshida, T.; Saijo, N.; Ozawa, S.; Sawada, J. Twelve novel single nucleotide polymorphisms in the CES2 gene encoding human carboxylesterase 2 (hCE-2). Drug Metab. Pharmacokinet., 2003, 18(5), 327-332.
68. Sai, K.; Saito, Y.; Tatewaki, N.; Hosokawa, M.; Kaniwa, N.; Ni-shimaki-Mogami, T.; Naito, M.; Sawada, J.; Shirao, K.; Hamagu-chi, T.; Yamamoto, N.; Kunitoh, H.; Tamura, T.; Yamada, Y.; Ohe, Y.; Yoshida, T.; Minami, H.; Ohtsu, A.; Matsumura, Y.; Saijo, N.; Okuda, H. Association of carboxylesterase 1A genotypes with iri-notecan pharmacokinetics in Japanese cancer patients. Br. J. Clin. Pharmacol., 2010, 70(2), 222-233.
69. Kubo, T.; Kim, S. R.; Sai, K.; Saito, Y.; Nakajima, T.; Matsumoto, K.; Saito, H.; Shirao, K.; Yamamoto, N.; Minami, H.; Ohtsu, A.; Yoshida, T.; Saijo, N.; Ohno, Y.; Ozawa, S.; Sawada, J. Functional characterization of three naturally occurring single nucleotide polymorphisms in the CES2 gene encoding carboxylesterase 2 (HCE-2). Drug Metab. Dispos., 2005, 33(10), 1482-1487. (Pubitemid 41323996)
70. Kim, S. R.; Sai, K.; Tanaka-Kagawa, T.; Jinno, H.; Ozawa, S.; Kaniwa, N.; Saito, Y.; Akasawa, A.; Matsumoto, K.; Saito, H.; Kamatani, N.; Shirao, K.; Yamamoto, N.; Yoshida, T.; Minami, H.; Ohtsu, A.; Saijo, N.; Sawada, J. Haplotypes and a novel defective allele of CES2 found in a Japanese population. Drug Metab. Dis-pos., 2007, 35(10), 1865-1872. (Pubitemid 47481580)
71. Horikawa, M.; Kato, Y.; Sugiyama, Y. Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats. Pharm. Res., 2002, 19(9), 1345-1353.
72. Haufroid, V. Genetic Polymorphisms of ATP-Binding Cassette transporters ABCB1 and ABCC2 and their impact on drug disposition. Curr. Drug Targets, 2011, 12(5), [631-46.
73. Shugarts, S.; Benet, L. Z. The role of transporters in the pharma-cokinetics of orally administered drugs. Pharm. Res., 2009, 26(9), 2039-2054.
74. de Jong, F. A.; Scott-Horton, T. J.; Kroetz, D. L.; McLeod, H. L.; Friberg, L. E.; Mathijssen, R. H.; Verweij, J.; Marsh, S.; Sparre-boom, A. Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clin. Pharmacol. Ther., 2007, 81(1), 42-49. (Pubitemid 46050866)
75. Glimelius, B.; Garmo, H.; Berglund, A.; Fredriksson, L. A.; Ber-glund, M.; Kohnke, H.; Bystrom, P.; Sorbye, H.; Wadelius, M. Prediction of irinotecan and 5-fluorouracil toxicity and response in patients with advanced colorectal cancer. Pharmacogenomics J., 2011, 11(1), 61-71.
76. Mathijssen, R. H.; Marsh, S.; Karlsson, M. O.; Xie, R.; Baker, S. D.; Verweij, J.; Sparreboom, A.; McLeod, H. L. Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin. Cancer Res., 2003, 9(9), 3246-3253. (Pubitemid 37086673)
77. Zhou, Q.; Sparreboom, A.; Tan, E. H.; Cheung, Y. B.; Lee, A.; Poon, D.; Lee, E. J.; Chowbay, B. Pharmacogenetic profiling across the irinotecan pathway in Asian patients with cancer. Br. J. Clin. Pharmacol., 2005, 59(4), 415-424. (Pubitemid 40523885)
78. Rhodes, K. E.; Zhang, W.; Yang, D.; Press, O. A.; Gordon, M.; Vallbohmer, D.; Schultheis, A. M.; Lurje, G.; Ladner, R. D.; Faz-zone, W.; Iqbal, S.; Lenz, H. J. ABCB1, SLCO1B1 and UGT1A1 gene polymorphisms are associated with toxicity in metastatic colo-rectal cancer patients treated with first-line irinotecan. Drug Metab. Lett., 2007, 1(1), 23-30.
79. Takara, K.; Obata, Y.; Yoshikawa, E.; Kitada, N.; Sakaeda, T.; Ohnishi, N.; Yokoyama, T. Molecular changes to HeLa cells on continuous exposure to cisplatin or paclitaxel. Cancer Chemother. Pharmacol., 2006, 58(6), 785-793. (Pubitemid 44351259)
80. Robey, R. W.; Medina-Perez, W. Y.; Nishiyama, K.; Lahusen, T.; Miyake, K.; Litman, T.; Senderowicz, A. M.; Ross, D. D.; Bates, S. E. Overexpression of the ATP-binding cassette half-transporter, ABCG2 (Mxr/BCrp/ABCP1), in flavopiridol-resistant human breast cancer cells. Clin. Cancer Res., 2001, 7(1), 145-152. (Pubitemid 32110217)
81. Takara, K.; Kitada, N.; Yoshikawa, E.; Yamamoto, K.; Horibe, S.; Sakaeda, T.; Nishiguchi, K.; Ohnishi, N.; Yokoyama, T. Molecular changes to HeLa cells on continuous exposure to SN-38, an active metabolite of irinotecan hydrochloride. Cancer Lett., 2009, 278(1), 88-96.
82. Xiang, X.; Jada, S. R.; Li, H. H.; Fan, L.; Tham, L. S.; Wong, C. I.; Lee, S. C.; Lim, R.; Zhou, Q. Y.; Goh, B. C.; Tan, E. H.; Chowbay, B. Pharmacogenetics of SLCO1B1 gene and the impact of *1b and *15 haplotypes on irinotecan disposition in Asian cancer patients. Pharmacogenet. Genomics, 2006, 16(9), 683-691. (Pubitemid 44223079)
83. Takane, H.; Miyata, M.; Burioka, N.; Kurai, J.; Fukuoka, Y.; Suyama, H.; Shigeoka, Y.; Otsubo, K.; Ieiri, I.; Shimizu, E. Severe toxicities after irinotecan-based chemotherapy in a patient with lung cancer: a homozygote for the SLCO1B1*15 allele. Ther. Drug Monit., 2007, 29(5), 666-668. (Pubitemid 47494070)
84. Sai, K.; Saito, Y.; Maekawa, K.; Kim, S. R.; Kaniwa, N.; Nishi-maki-Mogami, T.; Sawada, J.; Shirao, K.; Hamaguchi, T.; Yama-moto, N.; Kunitoh, H.; Ohe, Y.; Yamada, Y.; Tamura, T.; Yoshida, T.; Matsumura, Y.; Ohtsu, A.; Saijo, N.; Minami, H. Additive effects of drug transporter genetic polymorphisms on irinotecan pharmacokinetics/pharmacodynamics in Japanese cancer patients. Cancer Chemother. Pharmacol., 2010, 66(1), 95-105.
85. Norris, M. D.; Smith, J.; Tanabe, K.; Tobin, P.; Flemming, C.; Scheffer, G. L.; Wielinga, P.; Cohn, S. L.; London, W. B.; Marshall, G. M.; Allen, J. D.; Haber, M. Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro. Mol. Cancer Ther., 2005, 4(4), 547-553. (Pubitemid 40601835)
86. Innocenti, F.; Kroetz, D. L.; Schuetz, E.; Dolan, M. E.; Ramirez, J.; Relling, M.; Chen, P.; Das, S.; Rosner, G. L.; Ratain, M. J. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. J. Clin. Oncol., 2009, 27(16), 2604-2614.
87. Larsen, A. K.; Skladanowski, A. Cellular resistance to topoi-somerase-targeted drugs: from drug uptake to cell death. Biochim. Biophys. Acta, 1998, 1400(1-3), 257-274. (Pubitemid 28475108)
88. Ehmer, U.; Lankisch, T. O.; Erichsen, T. J.; Kalthoff, S.; Freiberg, N.; Wehmeier, M.; Manns, M. P.; Strassburg, C. P. Rapid allelic discrimination by TaqMan PCR for the detection of the Gilbert's syndrome marker UGT1A1*28. J. Mol. Diagn., 2008, 10(6), 549-552.
89. Mathijssen, R. H.; Gurney, H. Irinogenetics: how many stars are there in the sky? J. Clin. Oncol., 2009, 27(16), 2578-2579.
90. Ando, Y.; Saka, H.; Ando, M.; Sawa, T.; Muro, K.; Ueoka, H.; Yokoyama, A.; Saitoh, S.; Shimokata, K.; Hasegawa, Y. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxic-ity: a pharmacogenetic analysis. Cancer Res., 2000, 60(24), 6921-6926. (Pubitemid 32059164)
91. Pillot, G. A.; Read, W. L.; Hennenfent, K. L.; Marsh, S.; Gao, F.; Viswanathan, A.; Cummings, K.; McLeod, H. L.; Govindan, R. A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report. J. Thorac. Oncol., 2006, 1(9), 972-978. (Pubitemid 47181365)
92. Sai, K.; Saito, Y.; Sakamoto, H.; Shirao, K.; Kurose, K.; Saeki, M.; Ozawa, S.; Kaniwa, N.; Hirohashi, S.; Saijo, N.; Sawada, J.; Yo-shida, T. Importance of UDP-glucuronosyltransferase 1A1*6 for ir-inotecan toxicities in Japanese cancer patients. Cancer Lett., 2008, 261(2), 165-171.
93. Zhou, Y. Y.; Lee, L. Y.; Ng, S. Y.; Hia, C. P.; Low, K. T.; Chong, Y. S.; Goh, D. L. UGT1A1 haplotype mutation among Asians in Singapore. Neonatology, 2009, 96(3), 150-155.
94. Innocenti, F.; Ratain, M. J. Irinotecan treatment in cancer patients with UGT1A1 polymorphisms. Oncology (Williston Park), 2003, 17(5 Suppl 5), 52-55.
95. Palomaki, G. E.; Bradley, L. A.; Douglas, M. P.; Kolor, K.; Dotson, W. D. Can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? An evidence-based review. Genet. Med., 2009, 11(1), 21-34.
96. Hu, Z. Y.; Yu, Q.; Zhao, Y. S. Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis. Eur. J. Cancer, 2010, 46(10), 1856-1865.
97. Maekawa, K.; Itoda, M.; Sai, K.; Saito, Y.; Kaniwa, N.; Shirao, K.; Hamaguchi, T.; Kunitoh, H.; Yamamoto, N.; Tamura, T.; Minami, H.; Kubota, K.; Ohtsu, A.; Yoshida, T.; Saijo, N.; Kamatani, N.; Ozawa, S.; Sawada, J. Genetic variation and haplotype structure of the ABC transporter gene ABCG2 in a Japanese population. Drug Metab. Pharmacokinet., 2006, 21(2), 109-121.
98. Deeken, J. F.; Slack, R.; Marshall, J. L. Irinotecan and uridine diphosphate glucuronosyltransferase 1A1 pharmacogenetics: to test or not to test, that is the question. Cancer, 2008, 113(7), 1502-1510.
99. O'Dwyer, P. J.; Catalano, R. B. Uridine diphosphate glucuronosyl- transferase (UGT) 1A1 and irinotecan: practical pharmacogenom-ics arrives in cancer therapy. J. Clin. Oncol., 2006, 24(28), 4534-4538. (Pubitemid 46630947)
100. Toffoli, G.; Cecchin, E.; Gasparini, G.; D'Andrea, M.; Azzarello, G.; Basso, U.; Mini, E.; Pessa, S.; De Mattia, E.; Lo Re, G.; Buonadonna, A.; Nobili, S.; De Paoli, P.; Innocenti, F. Genotype-driven phase I study of irinotecan administered in combination with fluorouracil/leucovorin in patients with metastatic colorectal cancer. J. Clin. Oncol., 2010, 28(5), 866-871.
101. Gold, H. T.; Hall, M. J.; Blinder, V.; Schackman, B. R. Cost effectiveness of pharmacogenetic testing for uridine diphosphate glucu-ronosyltransferase 1A1 before irinotecan administration for metas-tatic colorectal cancer. Cancer, 2009, 115(17), 3858-3867.
102. Mathijssen, R. H.; Verweij, J.; de Jonge, M. J.; Nooter, K.; Stoter, G.; Sparreboom, A. Impact of body-size measures on irinotecan clearance: alternative dosing recommendations. J. Clin. Oncol., 2002, 20(1), 81-87. (Pubitemid 34032599)
103. de Jong, F. A.; Mathijssen, R. H.; Xie, R.; Verweij, J.; Sparreboom, A. Flat-fixed dosing of irinotecan: influence on pharmacokinetic and pharmacodynamic variability. Clin. Cancer Res., 2004, 10(12 Pt 1), 4068-4071. (Pubitemid 38812483)